Extending Survival in Glioblastoma: Real-World Evidence of Post-Progression Benefit From Tumor-Treating Fields Therapy
Author(s)
Gordon V. Chavez, BA1, Patrick Conlon, PhD2, Bruce Wang, PhD3.
1Senior Manager, Research Initiatives & RWE, Novocure, New York, NY, USA, 2Novocure, Portsmouth, NH, USA, 3Novocure, New York, NY, USA.
1Senior Manager, Research Initiatives & RWE, Novocure, New York, NY, USA, 2Novocure, Portsmouth, NH, USA, 3Novocure, New York, NY, USA.
OBJECTIVES: Glioblastoma (GBM) is the most common primary central nervous system tumor. It is highly aggressive with a poor prognosis. Tumor Treating Fields (TTFields) therapy has been shown to improve survival in newly diagnosed GBM. Our objective was to estimate the impact on survival of continuing TTFields therapy after the first occurrence of disease progression.
METHODS: Utilizing electronic medical records from the xCures real-world data platform and administrative device status records, this study analyzed newly diagnosed GBM patients who began TTFields therapy in various US settings between January 2, 2019 and February 22, 2021. Patients were classified as continuing TTFields post-progression if they remained on TTFields for at least 30 days after disease progression. Patients who ended TTFields therapy before 30 days had elapsed were classified as discontinuers at progression. To exclude cases of rapid clinical deterioration, discontinuers were also required to survive for at least 90 days after their progression event. Propensity score matching was applied to match patients based on key prognostic factors and time to first progression (TTP) among patients in each group.
RESULTS: A total of 510 patients were included in the matched cohort (255 patients in each group). Characteristics were well balanced between groups. Patients who continued using TTFields after their first progression event demonstrated significantly higher overall survival (OS) from time of diagnosis (HR=0.67, P<0.0001) as well as significantly higher OS from time of progression (HR=0.59, P<0.0001) compared with those discontinuing TTFields. Median OS from time of progression was 13.73 months for continuers vs 8.43 months for discontinuers. Median TTP was 12.23 months for continuers vs 11.73 months for discontinuers.
CONCLUSIONS: Assessment of survival outcomes among a large real-world cohort of TTFields users suggests patients are likely to benefit from TTFields therapy even after their first disease progression event.
METHODS: Utilizing electronic medical records from the xCures real-world data platform and administrative device status records, this study analyzed newly diagnosed GBM patients who began TTFields therapy in various US settings between January 2, 2019 and February 22, 2021. Patients were classified as continuing TTFields post-progression if they remained on TTFields for at least 30 days after disease progression. Patients who ended TTFields therapy before 30 days had elapsed were classified as discontinuers at progression. To exclude cases of rapid clinical deterioration, discontinuers were also required to survive for at least 90 days after their progression event. Propensity score matching was applied to match patients based on key prognostic factors and time to first progression (TTP) among patients in each group.
RESULTS: A total of 510 patients were included in the matched cohort (255 patients in each group). Characteristics were well balanced between groups. Patients who continued using TTFields after their first progression event demonstrated significantly higher overall survival (OS) from time of diagnosis (HR=0.67, P<0.0001) as well as significantly higher OS from time of progression (HR=0.59, P<0.0001) compared with those discontinuing TTFields. Median OS from time of progression was 13.73 months for continuers vs 8.43 months for discontinuers. Median TTP was 12.23 months for continuers vs 11.73 months for discontinuers.
CONCLUSIONS: Assessment of survival outcomes among a large real-world cohort of TTFields users suggests patients are likely to benefit from TTFields therapy even after their first disease progression event.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO120
Topic
Clinical Outcomes, Methodological & Statistical Research, Real World Data & Information Systems
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Neurological Disorders, Oncology